Systematic review of the economic impact of cerebral palsy.
Cerebral palsy costs explode with severity—families and welfare systems pay huge non-medical bills that BCBAs can help secure funding for.
01Research in Context
What this study did
The team hunted for every paper that counted the dollars cerebral palsy costs.
They found 22 studies from around the world and pulled the numbers together.
Kids were grouped by how much help they needed: mild, moderate, or severe.
What they found
Price tags climb fast as severity grows.
Families pay for extra therapy, special seats, and lost work days.
Welfare systems also bleed cash for aides, transport, and respite that insurance never covers.
How this fits with other research
Tezcan et al. (2013) showed CP drops quality-of-life lower than spina bifida.
Lower quality-of-life scores feed the dollar models Utsana reviewed, so the stories match.
Ten Hoopen et al. (2025) listed 15 barriers parents hit when hunting respite care.
Those barriers explain why Utsana finds families burning money on private help.
Samtani et al. (2021) mapped cancer-care gaps for people with IDD.
Both reviews scream the same message: chronic neuro-disability care is under-studied and over-priced.
Why it matters
When you write a treatment plan, picture the hidden bill.
A severe-CP child may need $40 000 a year in non-medical supports.
Push for funding at the IEP table: list each extra cost the review uncovered.
Ask insurers to cover respite and gear before parents burn out or quit jobs.
Want CEUs on This Topic?
The ABA Clubhouse has 60+ free CEUs — live every Wednesday. Ethics, supervision & clinical topics.
Join Free →Add a line in your next IEP goal sheet that lists the yearly non-medical cost estimate and cite the Utsana review to justify assistive tech or respite funding.
02At a glance
03Original abstract
BACKGROUND: Cerebral palsy (CP) and its associated conditions can pose a significant economic burden on families, the health care system and the general economy. The boundary for inclusion of costs in research can vary substantially across studies. AIMS: To summarize the evidence for burden of disease for CP including the impacts on the health system, the community and carers. METHODS: Literature was identified from Ovid Medline, Embase, CINHAL, PsyInfo, Econlit, Health Economic Evaluation Database (HEED) and NHS Economic Evaluation Database (NHS EED) in the Cochrane Library. The search was restricted to articles published in English between 1970 and April 2016. All costs were converted to $USD 2016 price. RESULTS: Twenty-two articles were included. Studies varied from snapshot cost descriptions to more complex lifetime estimates, from prevalence-based to incidence-based studies, and from inclusion to exclusion of non-medical costs. There was a strong positive relationship between CP severity and expenditure. Significant costs were incurred by families and the welfare system to facilitate school and community engagement. CONCLUSION: Facilitating participation for people with CP involves substantial expense. The size, nature and distribution of the economic burden emphasises the importance of finding effective strategies to reduce the risk and severity of CP, together with how it is financed.
Research in developmental disabilities, 2018 · doi:10.1016/j.ridd.2018.06.012